PMID: 9542905May 23, 1998Paper

Emergence of multidrug resistance in ubiquitous and dominant Pseudomonas aeruginosa serogroup O:11. The Greek Pseudomonas Aeruginosa Study Group

Journal of Clinical Microbiology
Panayotis T. TassiosN J Legakis

Abstract

The serotypes of 88 nonreplicate nosocomial Pseudomonas aeruginosa isolates from 11 Greek hospitals were studied in relation to their antibiotic susceptibilities. Rates of resistance to beta-lactams, aminoglycosides, and quinolones ranged from 31 to 65%, except for those to ceftazidime (15%) and imipenem (21%). Four serotypes were dominant: O:12 (25% of isolates), O:1 (17%), O:11 (16%), and O:6 (10%). Multidrug resistance rates in the major serogroups O:12 (91%) and O:11 (79%) were higher than those in serogroups O:1 (40%) and O:6 (43%). Further typing with respect to pulsed-field gel electrophoresis patterns following XbaI digestion of genomic DNA discriminated the isolates into 74 types. Pulsed-field gel electrophoresis revealed that the ubiquitous O:12 group was genetically homogeneous, since 95% of strains belonged to two clusters of genotypic similarity, while the O:11 strains, present in 8 of the 11 hospitals, were distributed among five such clusters. Therefore, apart from the already reported O:12 multidrug-resistant European clone, an O:11 population, characterized by a serotype known to be dominant in the environment and the hospital in several parts of the world, but previously not associated with multidrug resistanc...Continue Reading

References

Dec 1, 1991·The Journal of Antimicrobial Chemotherapy·J Patzer, D Dzierzanowska
Jun 1, 1987·European Journal of Clinical Microbiology·N J LegakisJ Papavassiliou
Aug 1, 1982·Journal of Clinical Microbiology·J J FarmerC D Brokopp
Sep 1, 1982·Journal of Clinical Microbiology·N J LegakisM Papapetropoulou
Mar 1, 1995·Journal of Clinical Microbiology·H GrundmannT L Pitt
Jul 1, 1993·The Journal of Hospital Infection·C L Poh, C C Yeo
Jul 1, 1993·The Journal of Hospital Infection·N J LegakisA C Vatopoulos
Aug 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A N ManiatisN J Legakis
Apr 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R C Spencer
Oct 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I ParaskakiN J Legakis
Feb 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L ArchibaldR Gaynes
Feb 1, 1997·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Panayotis T. TassiosNicholas J. Legakis

❮ Previous
Next ❯

Citations

Apr 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A C GalesR Ramphal
Jan 22, 2003·Environmental Microbiology·Jean-Paul PirnayPierre Cornelis
Nov 1, 2011·Journal of Bacteriology·Tatsuya TadaTeruo Kirikae
Jun 19, 2002·Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health·B SeolM Bedeković
Nov 26, 2009·PloS One·Jean-Paul PirnayDaniel De Vos
Jul 10, 1999·Journal of Bacteriology·C R DeanJ B Goldberg
Apr 13, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Theodoros KarampatakisEmmanuel Roilides
Sep 20, 2017·Journal of Medical Microbiology·Júlia RadóSándor Szoboszlay
Mar 8, 2005·Journal of Clinical Microbiology·A DeplanoM J Struelens
Nov 24, 2006·Journal of Clinical Microbiology·Jun-Ichiro SekiguchiTeruo Kirikae
May 8, 2003·Journal of Clinical Microbiology·Karine FaureJeanine P Wiener-Kronish
Nov 8, 2003·Journal of Clinical Microbiology·Lucie OntenienteGilles Vergnaud
Nov 18, 2003·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A TsakrisN J Legakis
Mar 4, 2000·Journal of Clinical Microbiology·A TsakrisD M Livermore
Oct 9, 1999·Journal of Natural Products·P GuiraudN Buarque De Gusmao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Panayotis T. TassiosN J Legakis
The Journal of Antimicrobial Chemotherapy
Jan A Patzer, Danuta Dzierzanowska
© 2022 Meta ULC. All rights reserved